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 ABSTRACT 
 Background  The systemic autoinfl ammatory disorders 
(SAID) share many clinical manifestations, albeit with 
variable patterns, intensity and frequency. A common 
defi nition of disease activity would be rational and useful 
in the management of these lifelong diseases. Moreover, 
standardised disease activity scores are required for the 
assessment of new therapies in constant development. 
The aim of this study was to develop preliminary activity 
scores for familial Mediterranean fever, mevalonate 
kinase defi ciency, tumour necrosis factor receptor-1-
associated periodic syndrome and cryopyrin-associated 
periodic syndromes (CAPS). 
 Methods  The study was conducted using two well-
recognised consensus formation methods: the Delphi 
technique and the nominal group technique. The results 
from a two-step survey and data from parent/patient 
interviews were used as preliminary data to develop the 
agenda for a consensus conference to build a provisional 
scoring system. 
 Results  24 of 65 experts in SAID from 20 countries 
answered the web questionnaire and 16 attended the 
consensus conference. There was consensus agreement 
to develop separate activity scores for each disease 
but with a common format based on patient diaries. 
Fever and disease-specifi c clinical variables were scored 
according to their severity. A fi nal score was generated 
by summing the score of all the variables divided by the 
number of days over which the diary was completed. 
Scores varied from 0 to 16 (0–13 in CAPS). These scores 
were developed for the purpose of clinical studies but 
could be used in clinical practice. 
 Conclusion  Using widely recognised consensus 
formation techniques, preliminary scores were obtained 
to measure disease activity in four main SAID. Further 
prospective validation study of this instrument will follow. 
 INTRODUCTION 
 The current defi nition of systemic autoinfl am-
matory diseases (SAID) covers a wide spectrum 
of disorders, all manifesting with excessive sys-
temic and organ-specifi c infl ammation ranging 
from rare monogenic hereditary recurrent fevers 
(HRFs) to a growing number of more com-
mon multifactorial diseases such as Crohn’s and 
Behçet’s diseases.  1  Traditionally, the HRFs include 
familial Mediterranean fever (FMF), mevalonate 
kinase defi ciency (MKD), tumour necrosis factor 
receptor-associated periodic syndrome (TRAPS) 
and cryo pyrin-associated periodic syndromes 
(CAPS). More recently, three other monogenic 
entities with variable development of fever have 
been added to this group: PAPA (pustulosis, acne, 
pyoderma gangrenosum, arthritis) syndrome, 
NLRP12-associated periodic syndrome and DIRA 
(interleukin-1 receptor antagonist defi ciency) syn-
drome. Febrile attacks of HRF are associated with 
acute biochemical infl ammation. Systemic amy-
loid A (AA) amyloidosis represents a serious long-
term complication. Blood tests show leucocytosis 
and elevated acute phase reactants (eg, C reac-
tive protein (CRP) and serum amyloid A protein 
(SAA)). However, specifi c diagnosis relies on iden-
tifi cation of mutations in the relevant genes (listed 
online at http://fmf.igh.cnrs.fr/ISSAID/infevers) 
and/or the recognition of specifi c clinical disease 
manifestations. All known proteins involved in 
hereditary SAID induce abnormalities of innate 
immunity, many of which through participating 
more or less directly in interleukin-1β (IL-1β) regu-
lation. Mutations in these proteins are thought to 
result in increased or prolonged secretion of this 
proinfl ammatory cytokine. Although IL-1β is not 
the only effector cytokine in driving the infl am-
matory process in all of these disorders, therapeu-
tic approaches targeting the IL-1β pathway have 
shown dramatic responses in almost all HRFs and 
especially in CAPS where double-blind placebo 
controlled studies have proven effi cacy.  2    3  
 While there are now increasing possibilities for 
targeted therapies in SAID, there is no consensus 
agreement on any outcome measures in this fi eld. 
Standardised disease activity scores are required to 
assess new medications  4  by using variables which 
can change over time. As SAID have similar clini-
cal manifestations, albeit with variable patterns, 
intensity and frequency,  5  we hypothesised that a 
common defi nition of disease activity scores would 
be a rational approach to improve the management 
of these lifelong diseases. This study aims to iden-
tify and score candidate measures of disease activ-
ity for the four main HRFs (FMF, MKD, CAPS and 
TRAPS). 
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had the opportunity to suggest and rate other variables that 
seemed relevant to them. Finally, they gave their opinion about 
the impact of the disease on their daily life. For the analysis, 
all variables were scored from 0 to 4 points according to their 
importance. The three variables identifi ed as most relevant by 
the patient were given an additional 2-point weighting. An aver-
age score for each variable was then calculated. 
 Step 4: Consensus conference (Nov 2009) 
 A 3-day consensus conference was held in Paris, France. 
Participants (listed as co-authors) were 16 international adult 
and paediatric physicians from seven countries whose exper-
tise covered the four SAID, two methodologists and a secretary. 
The main goal of the conference was to defi ne, through NGT, 
the domains and variables to include in the provisional activity 
score. For each question, participants spent several minutes indi-
vidually considering all the possible ideas. The ideas were col-
lected by sharing them in a ‘round robin’ format (one response 
per person each time). Consensus was obtained if 13 of the 16 
experts provided the same response. Otherwise, participants 
evaluated suggested ideas, shared thoughts, deleted duplicate 
items and individually voted for the best response until reaching 
a consensus. The results of the Delphi surveys and interviews 
with parents/patients were considered, but the expert fi nal opin-
ion was used as the gold standard. To establish disease-specifi c 
activity scores, a brief review of the specifi c manifestations of 
each SAID was presented and then experts were divided into 
disease-specifi c groups. Each group worked separately and then 
presented its conclusions to all the participants. All experts dis-
cussed the proposals and the fi nal activity score was developed 
by a second consensus. 
 RESULTS 
 Delphi surveys 
 The response rate to the fi rst round was 37% (24/65 experts 
answered the questionnaire). The experts agreed on the neces-
sity of global disease assessment scores. Among the 22 variables 
initially suggested, 8 reached consensus and the experts agreed 
that frequency, duration of joint symptoms and the number of 
affected joints better assess joint disease activity ( box 1 ). The 
experts suggested fi ve new variables after the fi rst round (eryth-
rocyte sedimentation rate (ESR), S100, hearing loss, urological 
symptoms and oral lesions), but above all they suggested some 
items to better assess joint disease activity, skin activity and CNS 
activity (data not shown). Nineteen of 24 experts completed the 
second survey which included these new variables and items. 
 METHODS 
 We used two widely accepted consensus formation methods  6  –  10  
specifi cally designed to combine opinions from a group of 
experts in a particular fi eld: the Delphi technique and the nomi-
nal group technique (NGT). The Delphi technique uses a series 
of well-defi ned questionnaire-based surveys. NGT is a struc-
tured face-to-face meeting designed to facilitate the consensus 
on the topic fi eld of study. This technique encourages equal par-
ticipation from group members and results in a set of prioritised 
solutions or recommendations. A two-step Delphi technique 
was used to reduce potential variables to a manageable number 
and these were then further defi ned by a NGT at a consensus 
meeting to develop preliminary scores. 
 The project was conducted in four steps. 
 Step 1: Delphi preparation meeting (Dec 2008) 
 The steering committee was composed by six international 
experts in SAID (4 French, 1 Italian, 1 Dutch) from French ref-
erence centres for SAID and EUROFEVER network partners, a 
methodologist and a study coordinator. During a fi rst face-to-
face meeting they generated and ranked preliminary variables 
refl ecting disease activity for the four main HRF: FMF, MKD, 
CAPS and TRAPS. At the end of this process, 22 variables ranked 
>2 and belonging to four different domains (clinical, biological, 
global assessment and quality of life) were chosen and submit-
ted to 65 preselected international experts. 
 Step 2: Delphi survey (Feb/Aug 2009) 
 Similarly to Ruperto  et al ,  7  we used a two-phase anonymous 
online survey (http://www.surveymonkey.com/) to select the 
variables which can be used to assess whether a patient has 
an active SAID. The surveys involved 65 experienced practis-
ing experts for SAID, members of the PReS and ISSAID societ-
ies from 20 different countries. In the fi rst survey, physicians 
were asked to choose relevant variables from the 22 selected by 
the study group. The number of selected variables could vary 
from 0 to 22 and new variables could be suggested. Experts 
also answered 13 targeted questions regarding evaluation of 
SAID activity and chose which aspects of some of the previ-
ous variables were relevant (eg, frequency, intensity, duration). 
The second survey consisted of variables and items for which 
no consensus was obtained (<80% agreement) in the fi rst round 
and new variables and items suggested by experts. However, 
experts refi ned these variables for each of the SAID separately. 
CAPS was subdivided into familial cold autoinfl ammatory syn-
drome (FCAS), Muckle-Wells syndrome (MWS) and chronic 
infantile neurological, cutaneous, articular (CINCA) also known 
as neonatal multisystem infl ammatory disease (NOMID). To 
increase the response to the Delphi survey, several recall emails 
were sent to the experts. The Delphi survey was anonymous 
and only those who replied to the fi rst round could participate 
in the second round. 
 Step 3: Parent and patient interviews (Sept/Oct 2009) 
 A standardised questionnaire was completed by parents/patients 
with one of the four SAID seen in four investigator centres in 
three countries over a 2-month period. In the event of language 
barriers, the investigator physician translated the questionnaire. 
Initially, patients/parents were asked to provide the three most 
relevant signs or symptoms indicating active disease. They 
then rated 35 potential SAID-related clinical signs or symptoms 
according to importance for perceived disease activity (no/mild/
moderate/important/very important). Patients/parents also 
Box 1 Variables selected by consensus (≥ 80%) for all 
systemic auto infl ammatory diseases during fi rst round of 
the Delphi survey
▶ Fever 92%
▶ Mean duration of attacks 92%
▶ Number of attacks/period 92%
▶ Joint symptoms 92%
  ▶ Frequency of attacks 90%
  ▶ Duration of attacks 95%
  ▶ Number of affected joints 80%
▶ Skin rash 92%
▶ Serositis 92%
▶ C reactive protein 92%
▶ Systemic amyloid A protein 80%
14_annrheumdis132613.indd   310 12/24/2010   2:30:02 PM
group.bmj.com on November 24, 2014 - Published by http://ard.bmj.com/Downloaded from 
Extended report
Ann Rheum Dis 2011;70:309–314. doi:10.1136/ard.2010.132613 311
manifest itself as abdominal pain, chest pain, arthritis/arthralgia 
or myalgia.  11  –  16  In our Delphi survey, physicians agreed with 
>90% consensus that fever, joint symptoms, serositis, chest and 
skin symptoms as well as the number and duration of attacks 
were important in the evaluation of FMF disease activity. Thus, 
the study group agreed that these features should be refl ected in 
the fi nal activity score for FMF. Patients with FMF may also have 
symptoms between disease fl ares such as arthralgia, myalgia 
and an erysipelas-like rash, which can also be important mea-
sures of disease activity.  12    14    15  
 MKD 
 MKD is caused by mutations in the mevalonate kinase gene 
inducing recurrent attacks characterised by fever, gastrointesti-
nal symptoms, lymphadenopathy and musculoskeletal symp-
toms. There was consensus that the frequency, intensity and 
duration of attacks should be considered in an activity score. 
Gastrointestinal symptoms are the most prominent and distress-
ing feature of MKD attacks,  17  and both experts and patients and 
their parents gave them priority ranking. Thus, the MKD provi-
sional score includes three gastrointestinal features: abdominal 
pain, diarrhoea and nausea/vomiting. Skin symptoms were not 
included in the fi nal score since group members felt that MKD-
related skin symptoms were not always related to the activity 
of the disease. 
 TRAPS 
 TRAPS is caused by mutations in the TNFRSF1A gene and results 
in recurrent but typically infrequent attacks of fever, varying in 
duration from a few days to several weeks.  18  The most char-
acteristic symptoms in association with fever include severe 
abdominal pain, localised myositis and skin manifestations (ery-
thema, periorbital oedema). As the whole clinical spectrum of 
Variables selected by consensus (≥80%) during the second round 
of the Delphi survey are shown in  table 1 . 
 Patient and parent interviews 
 Nineteen patients/parents from three countries participated in a 
standardised interview. One questionnaire was incomplete so 18 
questionnaires were analysed (8 women and 10 men aged 2.5–
47.4 years (mean 13.7, median 12.1); 3 with FMF, 7 with MKD, 
4 with TRAPS, 2 with MWS and 2 with CINCA/NOMID). For 
each variable the mean score varied from 0 to 6. A mean score of 
≥4 identifi ed variables which the patients considered to be very 
important. These were: fever for FMF; fever, lymphadenopathy, 
abdominal pain and anorexia for MKD; fever, abdominal pain, 
fatigue, intensity of attacks and intensity of fever for TRAPS; 
fever and fatigue for MWS; presence of skin rash and its fre-
quency for CINCA/NOMID. 
 Consensus conference 
 The fi rst part of the consensus conference was devoted to the 
analysis and discussion of the preliminary data from the Delphi 
surveys and interviews with patients and parents. 
 There was a consensus to build a scoring system which would 
be a useful instrument in clinical trials and to develop separate 
activity scores for each disease with a shared format. The clini-
cal disease activity scores would be obtained from a patient 
diary completed during attacks. Fever was scored as absent (0) 
or present (1) and disease-specifi c clinical variables were scored 
according to their severity from 0 to 3. 
 Reports from small group workshops regarding each SAID 
 FMF 
 FMF is caused by mutations in pyrin which cause recurrent 
attacks characterised by fever and serositis. Serositis may 
 Table 1  Variables selected by consensus ( ≥ 80%) during second round of the Delphi survey
 Variables  FMF (%)  TRAPS (%)  MKD (%) 
 CAPS 
 FCAS (%)  MWS (%)  NOMID (%) 
Fatigue  82 81 87 87 82
Number of days of illness in the past 3 months 94 88 100 93 87 82
Intensity of attacks 89  81    
 Arthritis 100      
 Arthralgia   87  80 87
 Measure of joint damage      94
 Presence absence of skin rash 94 81 82 100 100 88
Intensity of skin rash    93 87 88
Frequency of skin rash    87 80  
 Number of days with skin rash in a month    93 93 82
Chest symptoms 94      
Muscle symptoms 82      
Gastrointestinal symptoms  100     
Painful lymphnodes   94    
 Hearing loss     93 82
Eye symptoms      82
Headaches      82
 Brain MRI      82
 Cognitive function test      94
 Funduscopy      88
Limitation of daily activity 89  87 87 80 81
Days of school /work loss 83  81    
Global DAS physician 83  81   88
Global DAS patient      82
 ESR 83      
 New variables/items suggested by experts after the fi rst round are shown in italics. 
 CAPS, cryopyrin-associated periodic syndromes; CINCA/NOMID, chronic infantile neurological, cutaneous, articular/neonatal onset multisystem infl ammatory disease; DAS, Disease 
Activity Score; ESR, erythrocyte sedimentation rate; FCAS, familial cold autoinfl ammatory syndrome; FMF, familial Mediterranean fever; MKD, mevalonate kinase defi ciency; MWS, 
Muckle-Wells syndrome; TRAPS, TNF receptor-1-associated periodic syndrome. 
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changes. All experts agreed that fatigue, quality of life and bio-
logical measures were different domains and should not be 
included in the disease activity score.  Tables 2 – 6 show diaries 
proposed by experts for each disease. The fi nal activity score 
consists of the sum of all variables (a+b+c+d+e+f) divided by 
the number of days over which the diary was completed. Since 
we have developed a daily diary for the disease activity score, 
we decided also to add information concerning the use of res-
cue treatment in anticipation of a possible composite score that 
we will develop. The use of rescue treatment will be noted by 
patients in the diary but should not be used in the computation 
of the activity score. 
 DISCUSSION 
 The use of a disease activity score is essential in clinical trials, 
both to assess the effi cacy of new therapies and to standardise 
assessments across trials.  20  A widely used and validated scoring 
system would facilitate comparison and meta-analysis of studies 
in the future, which would be particularly useful in the context 
of these rare diseases. Unlike other infl ammatory diseases,  21  
no activity scores for either adults or children are available for 
SAID, which limits the ability to assess current treatments or to 
appreciate whether disease activity predicts the development of 
serious long-term complications such as permanent hearing loss, 
vision loss or AA amyloidosis. In this context, a disease activity 
score applicable to adults and to children is of great importance. 
To assess the course of the disease and to detect clinically impor-
tant change with respect to a therapeutic intervention, a mea-
sure must be sensitive to change. In FMF, disease severity scores 
were published for adults and a severity score was suggested for 
children,  22  –  24  but unlike disease activity scores, severity scores 
include variables that do not change with time (eg, age of onset) 
or include damage (eg, amyloidosis). 
 As some clinical manifestations are similar between the 
SAID, the experts decided to construct activity scores which 
share the same format but are adapted to each disease. For 
all SAID, both experts and the study group considered that 
the duration and frequency of the attacks were important 
indicators of disease activity. In building these scores, the 
study group agreed that using a single format would facilitate 
standardisation and be easier to use. The scores are gener-
ated from a standardised patient diary which can easily be 
completed by the patient or parents. After validation, these 
tools could be adopted in future clinical trials, epidemiological 
research and/or routine clinical practice. For each SAID, the 
use of a prospective patient-based diary was felt to be the best 
way to accurately assess the major symptoms including inten-
sity, frequency and duration. Evaluation periods for which 
the diary is completed can be adapted as clinically appropri-
ate—a 3-month period survey is probably suitable for FMF 
TRAPS is very heterogeneous and not yet completely defi ned, 
especially in patients carrying non-cysteine TNFR mutations, 
the study group decided to add an assessment of overall TRAPS-
related symptoms in the disease activity score. In addition to the 
requirement for pain-relieving medications, the group decided 
to quantify the amount of administered corticosteroids, even 
though these two were not included in the calculation of the 
fi nal score. 
 CAPS 
 CAPS comprises a spectrum of three well-recognised clini-
cal entities that increase in severity from FCAS to MWS and 
CINCA/NOMID syndrome.  19  While symptoms in FCAS are 
classically triggered by cold exposure and feelings of chills that 
are most pronounced in the evening, symptoms in CINCA/
NOMID are typically continuous and often headaches and nau-
sea are most pronounced in the morning. Symptoms shared by 
the entire spectrum of CAPS comprise fever, chills, conjuncti-
vitis, diffuse urticaria, headaches and myalgia/arthralgia. The 
intensity of headaches may refl ect the intensity of CNS disease, 
especially the chronic meningitis encountered in patients with 
CAPS. The course of the disease and the disease-associated 
disability varies among patients with CAPS. Those with FCAS 
primarily experience episodic attacks with very little if any per-
manent organ damage, while patients with CINCA/NOMID 
usually have continuous disease resulting in debilitating organ 
damage. The results from the Delphi process and from the 
expert meeting showed consensus on daily evaluation of fever, 
limb pain, skin rash, conjunctivitis and headaches to assess 
CAPS disease activity. 
 Table 2 shows the selected variables for each disease. A fi nal 
score was generated by calculating the sum of the scores for all 
variables divided by the number of days over which the diary 
was completed. Scores could vary from 0 to 16 (0–13 in CAPS). 
Serial disease activity measurement should be obtained with 
suffi ciently long intervals (eg, 3–6 months) to detect meaningful 
 Table 2  Variables selected during consensus conference to assess 
disease activity 









Abdominal pain Abdominal pain Abdominal pain Limb pain
Arthralgia or myalgia Nausea/vomiting Limb pain Conjunctivitis
Swelling of the joints Diarrhoea Eye manifestations Headaches
Chest pain Limb pain Skin rash Skin rash
Skin rash Painful lymph nodes Overall TRAPS 
symptoms
 
 CAPS, cryopyrin-associated periodic syndromes; FMF, familial Mediterranean fever; 
MKD, mevalonate kinase defi ciency;TRAPS, TNF receptor-1-associated periodic 
syndrome. 
 Table 3  Diary for patients with familial Mediterranean fever (FMF) 
FMF-related symptoms today
 Name:  Month:  Year: 
 Days  Fever ≥38°C (100.4°F)  Abdominal pain  Chest pain  Arthralgia or myalgia  Swelling of the joints  Skin rash  Pain relief taken 
 Scored as:  0 or 1  0–3  0–3  0–3  0–3  0–3  0 or 1 
1        
2        
…        
31        
Total (a) (b) (c) (d) (e) (f) Total 
(a+b+c+d+e+f)
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included in a composite score. The activity score aims to be 
the fi rst step in the construction of a more elaborate and com-
plete composite score. Some standardised instruments to assess 
the global impact of the disease such as visual analogue scales 
were also proposed. The need for rescue treatment (such as 
corticosteroids), the results of biological measurements such as 
CRP and SAA, quality of life, organ-specifi c infl ammation and 
disease-associated damage (including joint destruction, growth 
retardation, hearing and vision loss, AA amyloidosis) are impor-
tant aspects in the evaluation of disease impact and the man-
agement of SAID. We aimed to include in the fi nal composite 
score variables that are easily assessable and tests which are 
available worldwide. CRP is a widely accessible, inexpensive 
and reliable measure of the hepatic non-specifi c infl ammatory 
acute phase response. Despite limited availability, the measure-
ment of SAA is the current gold standard in determining the 
prognosis and response to treatment in studies assessing the 
development of AA amyloidosis.  14    24  Both blood tests, CRP 
and SAA can be helpful in episodic diseases if assayed between 
attacks since evidence of complete normalisation suggests con-
trol of subclinical infl ammation.  25  Evaluation of fatigue, a very 
common symptom emphasised by patients and experts, as well 
as the assessment of quality of life are major parameters that 
could be included in a composite score. Existing quality of life 
and MKD but could be longer in TRAPS and shorter in CAPS. 
The method of calculation of the score is straightforward and 
provides a global score ranging from 0 to 16 (0–13 for CAPS) 
for the evaluation period. 
 Selection of the variables included in the score was based on 
physicians’ and patients’ opinion. This process had some limi-
tations. First, the fi nal response rate of the Delphi survey was 
limited as only 19 of the 65 experts approached completed both 
questionnaires. Among the physicians who did not answer, we 
hypothesised that some of them were probably not interested 
in the study but that most were not suffi ciently confi dent to 
provide an opinion on all SAID as some of these conditions 
are very rare with an incidence of approximately 1 per million. 
Also, we did not include enough patients to be completely 
certain that their opinions were representative. However, the 
main point of this paper is the result of the consensus confer-
ence. Both combined physician (Delphi technique) and patient 
views (interviews) were used as a starting point for experts 
during the consensus conference to fuel the discussion and 
were not used directly for the construction of the scores. 
 While disease activity is important, it does not summarise 
the overall effect of disease on patients with SAID. During the 
consensus conference, experts emphasised the need to collect 
data on additional disease parameters, some of which could be 
 Table 4  Diary for patients with mevalonate kinase defi ciency (MKD) 
 MKD-related symptoms today 
 Name:  Month:  Year: 
 Days  Fever ≥38°C (100.4°F)  Abdominal pain  Painful lymph nodes  Limb pain  Nausea/vomiting  Diarrhoea  Pain relief taken 
 Scored as:  0 or 1  0–3  0–3  0–3  0–3  0–3  0 or 1 
1        
2        
…        
31        
Total (a) (b) (c) (d) (e) (f) Total 
(a+b+c+d+e+f)
 Table 6  Diary for patients with cryopyrin-associated periodic syndromes (CAPS) 
 CAPS-related symptoms today 
 Name:  Month:  Year: 
 Days  Fever ≥38°C (100.4°F) or chills  Eye manifestations  Headaches  Limb pain  Skin rash  Pain relief taken 
 Scored as:  0 or 1  0–3  0–3  0–3  0–3  0 or 1 
1       
2       
…       
31       
Total (a) (b) (c) (d) (e) Total (a+b+c+d+e)
 Table 5  Diary for patients with tumour necrosis factor receptor-1-associated periodic syndrome (TRAPS) 
 TRAPS-related symptoms today  Medication taken for TRAPS today 
 Name: Month:  Year: 
 Days  Fever ≥38°C (100.4°F)  Overall TRAPS symptoms  Abdominal pain  Limb pain  Skin rash  Eye manifestations  Pain relief taken  Prednisolone 
 Scored as:  0 or 1  0–3  0–3  0–3  0–3  0–3  0 or 1  mg 
1         
2         
…         
31         
Total (a) (b) (c) (d) (e) (f) Total (a+b+c+d+e+f)
14_annrheumdis132613.indd   313 12/24/2010   2:30:02 PM
group.bmj.com on November 24, 2014 - Published by http://ard.bmj.com/Downloaded from 
Extended report
Ann Rheum Dis 2011;70:309–314. doi:10.1136/ard.2010.132613 314
 REFERENCES 
  1.  Touitou  I,  Koné-Paut  I.  Autoinfl ammatory diseases.  Best Pract Res Clin Rheumatol 
 2008 ; 22 : 811 – 29 . 
  2.  Lachmann  HJ,  Kone-Paut  I,  Kuemmerle-Deschner  JB,  et al.  Use of canakinumab in 
the cryopyrin-associated periodic syndrome.  N Engl J Med  2009 ; 360 : 2416 – 25 . 
  3.  Hoffman  HM,  Throne  ML,  Amar  NJ,  et al.  Effi cacy and safety of rilonacept (inter-
leukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from 
two sequential placebo-controlled studies.  Arthritis Rheum  2008 ; 58 : 2443 – 52 . 
  4.  Sinha  I,  Jones  L,  Smyth  RL,  et al.  A systematic review of studies that aim to deter-
mine which outcomes to measure in clinical trials in children.  PLoS Med  2008 ; 5 : e96 . 
  5.  Drenth  JP,  van der Meer  JW.  Hereditary periodic fever.  N Engl J Med 
 2001 ; 345 : 1748 – 57 . 
  6.  Batthish  M,  Schneider  R,  Ramanan  AV,  et al.  What does “active disease” mean? 
patient and part5ent perceptions of disease activity in the systemic arthritis form of 
juvenile idiopathic arthritis (SO-JIA).  Rheumatology (Oxford)  2005 ; 44 : 796 – 9 . 
  7.  Ruperto  N,  Ravelli  A,  Murray  KJ,  et al.  Preliminary core sets of measures for disease 
activity and damage assessment in juvenile systemic lupus erythematosus and 
juvenile dermatomyositis.  Rheumatology (Oxford)  2003 ; 42 : 1452 – 9 . 
  8.  Ruperto  N,  Meiorin  S,  Iusan  SM,  et al.  Consensus procedures and their role in 
pediatric rheumatology.  Curr Rheumatol Rep  2008 ; 10 : 142 – 6 . 
  9.  Jones  J,  Hunter  D.  Consensus methods for medical and health services research. 
 BMJ  1995 ; 311 : 376 – 80 . 
 10.  Zulian  F,  Woo  P,  Athreya  BH,  et al.  The Pediatric Rheumatology European Society/
American College of Rheumatology/European League against Rheumatism 
provisional classifi cation criteria for juvenile systemic sclerosis.  Arthritis Rheum 
 2007 ; 57 : 203 – 12 . 
 11.  Kallinich  T,  Haffner  D,  Niehues  T,  et al.  Colchicine use in children and adolescents 
with familial Mediterranean fever: literature review and consensus statement. 
 Pediatrics  2007 ; 119 : e474 – 83 . 
 12.  Livneh  A,  Langevitz  P,  Zemer  D,  et al.  The changing face of familial Mediterranean 
fever.  Semin Arthritis Rheum  1996 ; 26 : 612 – 27 . 
 13.  Livneh  A,  Langevitz  P,  Zemer  D,  et al.  Criteria for the diagnosis of familial 
Mediterranean fever.  Arthritis Rheum  1997 ; 40 : 1879 – 85 . 
 14.  Samuels  J,  Ozen  S.  Familial Mediterranean fever and the other autoinfl ammatory 
syndromes: evaluation of the patient with recurrent fever.  Curr Opin Rheumatol 
 2006 ; 18 : 108 – 17 . 
 15.  Tunca  M,  Akar  S,  Onen  F,  et al.  Familial Mediterranean fever (FMF) in Turkey: results 
of a nationwide multicenter study.  Medicine (Baltimore)  2005 ; 84 : 1 – 11 . 
 16.  Yalçinkaya  F,  Ozen  S,  Ozçakar  ZB,  et al.  A new set of criteria for the diagnosis of 
familial Mediterranean fever in childhood.  Rheumatology (Oxford)  2009 ; 48 : 395 – 8 . 
 17.  van der Hilst  JC,  Bodar  EJ,  Barron  KS,  et al.  Long-term follow-up, clinical features, 
and quality of life in a series of 103 patients with hyperimmunoglobulinemia D 
syndrome.  Medicine (Baltimore)  2008 ; 87 : 301 – 10 . 
 18.  Dodé  C,  André  M,  Bienvenu  T,  et al.  The enlarging clinical, genetic, and population 
spectrum of tumor necrosis factor receptor-associated periodic syndrome.  Arthritis 
Rheum  2002 ; 46 : 2181 – 8 . 
 19.  Aksentijevich  I,  D Putnam  C,  Remmers  EF,  et al.  The clinical continuum of 
cryopyrinopathies: novel CIAS1 mutations in North American patients and a new 
cryopyrin model.  Arthritis Rheum  2007 ; 56 : 1273 – 85 . 
 20.  Singh  JA,  Solomon  DH,  Dougados  M,  et al.  Development of classifi cation and 
response criteria for rheumatic diseases.  Arthritis Rheum  2006 ; 55 : 348 – 52 . 
 21.  Consolaro  A,  Ruperto  N,  Bazso  A,  et al.  Development and validation of a composite 
disease activity score for juvenile idiopathic arthritis.  Arthritis Rheum  2009 ; 61 : 658 – 66 . 
 22.  Mor  A,  Shinar  Y,  Zaks  N,  et al.  Evaluation of disease severity in familial Mediterranean 
fever.  Semin Arthritis Rheum  2005 ; 35 : 57 – 64 . 
 23.  Pras  E,  Livneh  A,  Balow  JE,  Jr,  et al.  Clinical differences between North African and 
Iraqi Jews with familial Mediterranean fever.  Am J Med Genet  1998 ; 75 : 216 – 9 . 
 24.  Ozen  S,  Aktay  N,  Lainka  E,  et al.  Disease severity in children and adolescents with 
familial Mediterranean fever: a comparative study to explore environmental effects on 
a monogenic disease.  Ann Rheum Dis  2009 ; 68 : 246 – 8 . 
 25.  Gillmore  JD,  Lovat  LB,  Persey  MR,  et al.  Amyloid load and clinical outcome in AA 
amyloidosis in relation to circulating concentration of serum amyloid A protein.  Lancet 
 2001 ; 358 : 24 – 9 . 
measures such as those used in rheumatological practice may 
have to be adapted and validated or a new specifi c scale cre-
ated. In the same way, global evaluation of disease activity by 
patients and the use of rescue treatments are of major impor-
tance in the management of SAID. In addition, disease-specifi c 
organ infl ammation and disease-associated damage predicts 
long-term health-related and more general patient outcomes 
and are of importance in assessing disease severity and long-
term effi cacy. Our consensus effort focused on the clinical activ-
ity score. 
 In conclusion, using standardised consensus formation tech-
niques, we have developed a preliminary scoring system to 
measure disease activity in four hereditary autoinfl ammatory 
disorders. We propose a single-format disease-adapted patient 
diary-based disease activity score which could be used in clinical 
research and possibly in clinical practice. In a next step we pro-
pose to conduct a prospective validation phase. For this, we will 
solicit centres participating in this study as well as other centres 
located in countries in which SAID are common. 
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